LDS/Medical Tests/Ranitidine, Serum or Urine

Ranitidine, Serum or Urine

Ranitidine is a first generation H2 receptor antagonist antihistamine. Ranitidine is used to treat individuals that suffer from gastrointestinal disorders, such as gastroesophageal reflux disease, heartburn, or Zollinger-Ellison syndrome. Ranitidine is a histamine antagonist. H1 and H2 antagonists, more commonly called antihistamines, have been produced to combat the effects of histamine.

Ranitidine is well absorbed after an oral dose and is minimally bound to protein (15%). The duration of the physiological action is usually between 4-6 hours. Ranitidine is metabolized via the cytochrome 450 enzyme system.

Although antihistamines have a wide use in our society today and can be obtained without a prescription, ranitidine is not considered in the clinical laboratory as a drug of abuse. Therefore, there are no immunoassay kits available for detection. General therapeutic concentrations of these drugs in the blood range from 0.5 to 5 mg/mL.

  • Therapeutic monitoring
  • Toxicity assessment
  • Patient compliance
Since these drugs are not considered as “drugs of abuse” any antihistamine detected should be viewed as “within the therapeutic range” or “outside the therapeutic range” or as “toxic.”

General Therapeutic Level: 0.5 - 5 mg/mL
Toxic level: varies by antihistamine

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy).

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days

Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Plasma specimens are acceptable if drawn in a heparin (green top) tube. Specimens should be spun and the serum or plasma separated and refrigerated.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Both LC/MS or GC/MS are considered the “gold standard” in testing for this class of drugs. Therefore, no additional confirmation of testing is required.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Forster City, CA: Biomedical Publications; 2002.
  • Gupta RN. Review: drug level monitoring: sedative hypnotics. J Chromatography. 1985;340:139-72.
  • Levine B (ed). Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press. Chapter 25, Antihistamines pp. 435-440; 2013.
  • Brunton LL, Chabner B, Knollman B, eds. Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Cooper FJ, Logan BK. Drugs and human performance fact sheets. Washington, DC: National Highway Traffic Safety Administration, U.S. Department of Transportation. DOT HS 809 725; 2004.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.
  • Stout PR, Farrell LJ. Opioids – Effects on human performance and behavior. Forensic Sci Rev. 2002;15:29-59.
  • Wu A (ed). Tietz, clinical guide to laboratory test, 4th ed. Philadelphia: WB Saunders; 2006.